Bionano Genomics, Inc. BNGO
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
3/9
Piotroski F — financial health
-31.33
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $28.5M | -$26.4M | — | — | $44.4M |
| 2024 | $30.8M | -$112.0M | — | — | $35.4M |
| 2023 | $36.1M | -$232.5M | — | — | $96.2M |
| 2022 | $27.8M | -$132.6M | — | — | $249.4M |
| 2021 | $18.0M | -$72.4M | — | — | $337.1M |
| 2020 | $8.5M | -$41.1M | — | -$38.3M | $35.1M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Dixon Jonathan V. | GENERAL COUNSEL | 2026-06-03 | Tax withheld | 24 | $1.30 |
| OLDAKOWSKI MARK | CHIEF OPERATING OFFICER | 2026-06-03 | Tax withheld | 27 | $1.30 |
| Chaubey Alka | CHIEF MEDICAL OFFICER | 2026-06-03 | Tax withheld | 24 | $1.30 |
| Adamchak Mark | Principal Accounting Officer | 2026-06-03 | Tax withheld | 7 | $1.30 |
| Chaubey Alka | CHIEF MEDICAL OFFICER | 2026-02-17 | Tax withheld | 18 | $1.10 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -31.33 (distress)
- Working capital / assets 0.305
- Retained earnings / assets -9.78
- EBIT / assets -0.453
- Equity / liabilities 1.523
Source: SEC EDGAR filings · CIK 0001411690 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.